Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3.

Published

Journal Article

OBJECTIVES: Genotype-specific associations between hepatitis C virus (HCV) and insulin resistance (IR) have been described, but a causal relationship remains unclear. This study investigated the association between a sustained virological response (SVR) and IR after chronic HCV therapy. METHODS: 2255 treatment-naive patients with chronic HCV genotype 1 or 2/3 were enrolled in two phase 3 trials of albinterferon alpha-2b versus pegylated interferon alpha-2a for 48 or 24 weeks, respectively. IR was measured before treatment and 12 weeks after treatment using homeostasis model assessment (HOMA)-IR. RESULTS: Paired HOMA-IR measurements were available in 1038 non-diabetic patients (497 with genotype 1; 541 with genotype 2/3). At baseline the prevalence of HOMA-IR >3 was greater in patients with genotype 1 than 2/3 (33% vs 27%; p=0.048). There was a significant reduction in the prevalence of IR in patients with genotype 1 achieving SVR (δ 10%; p<0.001), but not in genotype 1 non-responders or those with genotype 2/3. Multivariate analysis indicated that SVR was associated with a significant reduction in mean HOMA-IR in patients with genotype 1 (p=0.004), but not in those with genotype 2/3, which was independent of body mass index, alanine transaminase, γ-glutamyl transpeptidase and lipid level changes. CONCLUSIONS: SVR is associated with a reduction in HOMA-IR in patients with HCV genotype 1 but not in those with genotype 2/3. Genotype 1 may have a direct effect on the development of IR, independent of host metabolic factors, and may be partially reversed by viral eradication.

Full Text

Duke Authors

Cited Authors

  • Thompson, AJ; Patel, K; Chuang, W-L; Lawitz, EJ; Rodriguez-Torres, M; Rustgi, VK; Flisiak, R; Pianko, S; Diago, M; Arora, S; Foster, GR; Torbenson, M; Benhamou, Y; Nelson, DR; Sulkowski, MS; Zeuzem, S; Pulkstenis, E; Subramanian, GM; McHutchison, JG; ACHIEVE-1 and ACHIEVE-2/3 Study Teams,

Published Date

  • January 2012

Published In

Volume / Issue

  • 61 / 1

Start / End Page

  • 128 - 134

PubMed ID

  • 21873466

Pubmed Central ID

  • 21873466

Electronic International Standard Serial Number (EISSN)

  • 1468-3288

Digital Object Identifier (DOI)

  • 10.1136/gut.2010.236158

Language

  • eng

Conference Location

  • England